{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:01:41Z","timestamp":1781179301574,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40256-026-00798-5","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T18:57:03Z","timestamp":1777748223000},"page":"453-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"given":"Muhammad Anas","family":"Faheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bazil","family":"Azeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3208-653X","authenticated-orcid":false,"given":"Talha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Asim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazheen Saleh","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mata-e-Alla","family":"Dogar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"798_CR1","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol [Internet]. 2020;76(25):2982\u20133021. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33309175\/."},{"issue":"11","key":"798_CR2","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1161\/CIR.0000000000000677","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation [Internet]. 2019;140(11):e563\u201395. https:\/\/doi.org\/10.1161\/CIR.0000000000000677.","journal-title":"Circulation [Internet]"},{"issue":"4","key":"798_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364.","journal-title":"JAMA"},{"key":"798_CR4","doi-asserted-by":"crossref","unstructured":"Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev [Internet]. 2020;2020(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32114706\/.","DOI":"10.1002\/14651858.CD003177.pub5"},{"key":"798_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1146\/annurev-pharmtox-051921-090208","volume":"63","author":"I Djuricic","year":"2023","unstructured":"Djuricic I, Calder PC. Pros and cons of long-chain omega-3 polyunsaturated fatty acids in cardiovascular health. Annu Rev Pharmacol Toxicol. 2023;63:383\u2013406. https:\/\/doi.org\/10.1146\/annurev-pharmtox-051921-090208.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"798_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"798_CR7","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA - Journal of the American Medical Association [Internet]. 2020;324(22):2268\u201380. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33190147\/.","DOI":"10.1001\/jama.2020.22258"},{"key":"798_CR8","unstructured":"RESPECT-EPA: Highly Purified EPA Appears to Reduce Risks of CV Events in Japanese CAD Patients on Statins - American College of Cardiology [Internet]. [cited 2025 Jun 6]. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/11\/01\/22\/00\/sun-7pm-respect-epa-aha-2022."},{"key":"798_CR9","doi-asserted-by":"crossref","unstructured":"Yang B, Tseng PT, Hu X, Zeng BY, Chang JPC, Liu Y, et al. Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials. Prog Lipid Res [Internet]. 2022;88. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36341839\/.","DOI":"10.1016\/j.plipres.2022.101196"},{"key":"798_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100997","volume":"38","author":"SU Khan","year":"2021","unstructured":"Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis. EClinicalMedicine. 2021;38:100997.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"798_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.025071","volume":"11","author":"X Zhang","year":"2022","unstructured":"Zhang X, Ritonja JA, Zhou N, Chen BE, Li X. Omega-3 polyunsaturated fatty acids intake and blood pressure: a dose\u2010response meta\u2010analysis of randomized controlled trials. J Am Heart Assoc. 2022;11(11):e025071.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"798_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-022-01075-x","volume":"25","author":"SCR Sherratt","year":"2023","unstructured":"Sherratt SCR, Libby P, Budoff MJ, Bhatt DL, Mason RP. Role of omega-3 fatty acids in cardiovascular disease: the debate continues. Curr Atheroscler Rep. 2023;25(1):1\u201317.","journal-title":"Curr Atheroscler Rep"},{"key":"798_CR13","unstructured":"PRISMA 2020 checklist\u2014PRISMA statement [Internet]. [cited 2025 June 6]. https:\/\/www.prisma-statement.org\/prisma-2020-checklist."},{"key":"798_CR14","unstructured":"PROSPERO [Internet]. [cited 2025 Jun 6]. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/."},{"key":"798_CR15","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Online) [Internet]. 2011;343(7829). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22008217\/.","DOI":"10.1136\/bmj.d5928"},{"key":"798_CR16","doi-asserted-by":"crossref","unstructured":"Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, et al. Evolution of Heterogeneity (I2) Estimates and Their 95% Confidence Intervals in Large Meta-Analyses. PLoS One [Internet]. 2012;7(7):e39471. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3405079\/.","DOI":"10.1371\/journal.pone.0039471"},{"key":"798_CR17","unstructured":"RevMan: Systematic review and meta-analysis tool for researchers worldwide | Cochrane RevMan [Internet]. [cited 2025 Jun 6]. Available from: https:\/\/revman.cochrane.org\/info."},{"issue":"7454","key":"798_CR18","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"Grading quality of evidence and strength of recommendations","year":"2004","unstructured":"Grading quality of evidence and strength of recommendations. BMJ. 2004Jun 19;328(7454):1490.","journal-title":"BMJ"},{"key":"798_CR19","doi-asserted-by":"crossref","unstructured":"Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, Matsui M, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol [Internet]. 2017;70(6):537\u201344. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28863874\/.","DOI":"10.1016\/j.jjcc.2017.07.007"},{"key":"798_CR20","doi-asserted-by":"crossref","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet [Internet]. 2007;369(9567):1090\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17398308\/.","DOI":"10.1016\/S0140-6736(07)60527-3"},{"issue":"6","key":"798_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","volume":"150","author":"K Miyauchi","year":"2024","unstructured":"Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, et al. Randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid (RESPECT-EPA). Circulation [Internet]. 2024;150(6):425\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065520.","journal-title":"Circulation [Internet]"},{"key":"798_CR22","doi-asserted-by":"crossref","unstructured":"Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J [Internet]. 2020;41(40):3925\u201332. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32860032\/.","DOI":"10.1093\/eurheartj\/ehaa652"},{"key":"798_CR23","doi-asserted-by":"crossref","unstructured":"Welty FK, Schulte F, Alfaddagh A, Elajami TK, Bistrian BR, Hardt M. Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B4. FASEB Journal [Internet]. 2021;35(4). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33749913\/.","DOI":"10.1096\/fj.202002471R"},{"key":"798_CR24","doi-asserted-by":"crossref","unstructured":"Crupi R, Cuzzocrea S. Role of EPA in Inflammation: mechanisms, effects, and clinical relevance. Biomolecules [Internet]. 2022;12(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35204743\/.","DOI":"10.3390\/biom12020242"},{"issue":"14","key":"798_CR25","doi-asserted-by":"publisher","first-page":"34076","DOI":"10.1161\/JAHA.123.034076","volume":"13","author":"SCR Sherratt","year":"2024","unstructured":"Sherratt SCR, Libby P, Dawoud H, Bhatt DL, Mason RP. Eicosapentaenoic acid improves endothelial nitric oxide bioavailability via changes in protein expression during inflammation. J Am Heart Assoc [Internet]. 2024;13(14):34076. https:\/\/doi.org\/10.1161\/JAHA.123.034076.","journal-title":"J Am Heart Assoc [Internet]"},{"key":"798_CR26","doi-asserted-by":"crossref","unstructured":"Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother [Internet]. 2018;103:1231\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29864903\/.","DOI":"10.1016\/j.biopha.2018.04.118"},{"key":"798_CR27","doi-asserted-by":"crossref","unstructured":"Sherratt S, Libby P, Bhatt D, Mason P. Eicosapentaenoic acid modulated expression of endothelial nitric oxide synthase (ENOS) and its modulators during inflammation. Atherosclerosis [Internet]. 2023;379:S3. Available from: https:\/\/www.atherosclerosis-journal.com\/action\/showFullText?pii=S0021915023040698.","DOI":"10.1016\/j.atherosclerosis.2023.06.052"},{"issue":"12","key":"798_CR28","doi-asserted-by":"publisher","first-page":"E673","DOI":"10.1161\/CIR.0000000000000709","volume":"140","author":"AC Skulas-Ray","year":"2019","unstructured":"Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 Fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation [Internet]. 2019;140(12):E673\u201391. https:\/\/doi.org\/10.1161\/CIR.0000000000000709.","journal-title":"Circulation [Internet]"},{"key":"798_CR29","doi-asserted-by":"crossref","unstructured":"Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? The Lancet [Internet]. 1978;312(8081):117\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/78322\/.","DOI":"10.1016\/S0140-6736(78)91505-2"},{"key":"798_CR30","doi-asserted-by":"crossref","unstructured":"Boehme AK, Esenwa C, Elkind MSV. Stroke risk factors, genetics, and prevention. Circ Res [Internet]. 2017;120(3):472\u201395. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28154098\/.","DOI":"10.1161\/CIRCRESAHA.116.308398"},{"key":"798_CR31","unstructured":"McDonagh M, Peterson K, Raina P, Chang S, Shekelle P. Avoiding bias in selecting studies. Methods guide for effectiveness and comparative effectiveness reviews [Internet]. 2008; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23487864\/."},{"key":"798_CR32","doi-asserted-by":"crossref","unstructured":"Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Advances in Nutrition [Internet]. 2012;3(1):1\u20137. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2161831322009620?via%3Dihub.","DOI":"10.3945\/an.111.000893"},{"issue":"1","key":"798_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-025-02513-w","volume":"24","author":"A Medoro","year":"2025","unstructured":"Medoro A, Graziano F, Cardinale G, Voccola S, Zotti T, Intrieri M, et al. The influence of FADS1 and ELOVL2 genetic polymorphisms on polyunsaturated fatty acid composition in response to fish oil supplementation. Lipids Health Dis [Internet]. 2025;24(1):1\u201310. https:\/\/doi.org\/10.1186\/s12944-025-02513-w.","journal-title":"Lipids Health Dis [Internet]"},{"key":"798_CR34","doi-asserted-by":"crossref","unstructured":"Shen SC, Gong C, Jin KQ, Zhou L, Xiao Y, Ma L. Omega-3 fatty acid supplementation and coronary heart disease risks: a meta-analysis of randomized controlled clinical trials. Front Nutr [Internet]. 2022;9:809311. Available from: www.frontiersin.org.","DOI":"10.3389\/fnut.2022.809311"},{"key":"798_CR35","doi-asserted-by":"crossref","unstructured":"Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP Concentrations and response to therapeutic agents. Clin Chem [Internet]. 2009;55(2):256\u201364. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19074515\/.","DOI":"10.1373\/clinchem.2008.117754"},{"key":"798_CR36","doi-asserted-by":"crossref","unstructured":"Bower JK, Lazo M, Juraschek SP, Selvin E. Within-person variability in high-sensitivity C-reactive protein. Arch Intern Med [Internet]. 2012;172(19):1519\u201321. Available from: https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/1356537.","DOI":"10.1001\/archinternmed.2012.3712"},{"key":"798_CR37","doi-asserted-by":"crossref","unstructured":"Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins. Diabetes Metab J [Internet]. 2022;46(4):517\u201332. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35929170\/.","DOI":"10.4093\/dmj.2022.0198"},{"key":"798_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.134046","volume":"445","author":"F Brucato","year":"2026","unstructured":"Brucato F, Tognola C, Moreo A, Bellomare M, Prencipe GP, Lettino M, et al. Eligibility for Icosapent ethyl in patients undergoing cardiac rehabilitation: A real-world cohort study. Int J Cardiol. 2026;445:134046. https:\/\/doi.org\/10.1016\/j.ijcard.2025.134046.","journal-title":"Int J Cardiol"},{"issue":"15","key":"798_CR39","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/eurjpc\/zwae184","volume":"31","author":"M Dinu","year":"2024","unstructured":"Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, Catapano AL, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31(15):1863\u201375. https:\/\/doi.org\/10.1093\/eurjpc\/zwae184.","journal-title":"Eur J Prev Cardiol"},{"key":"798_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4593325","volume":"2022","author":"L De Luca","year":"2022","unstructured":"De Luca L, Colivicchi F, Gabrielli D, Lucci D, Grippo G, Piemonte F, et al. Incidence, characteristics, and management of patients with recurrent myocardial infarctions: insights from the EYESHOT POST-MI. J Interv Cardiol. 2022;2022:4593325. https:\/\/doi.org\/10.1155\/2022\/4593325.","journal-title":"J Interv Cardiol"},{"key":"798_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133608","volume":"439","author":"C Tognola","year":"2025","unstructured":"Tognola C, Bernasconi D, Intravaia RCM, Brioschi G, Toscani G, Algeri M, et al. Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation program. Int J Cardiol. 2025;439:133608. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133608.","journal-title":"Int J Cardiol"},{"key":"798_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120411","volume":"408","author":"PCE Schuitema","year":"2025","unstructured":"Schuitema PCE, Visseren FLJ, Nordestgaard BG, Teraa M, van der Meer MG, Ruigrok YM, et al. Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and intensity of lipid-lowering therapy in patients with established cardiovascular disease. Atherosclerosis. 2025;408:120411. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120411.","journal-title":"Atherosclerosis"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00798-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00798-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00798-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:38:45Z","timestamp":1781177925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00798-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00798-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Muhammad Anas Faheem, Bazil Azeem, Talha Ali, Rabia Asim, Tazheen Saleh Muhammad, Mata-e-Alla Dogar, and Muhammad Abdullah Naveed declare no competing interests\/conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests\/Conflict of Interest"}},{"value":"Not applicable. This article is based on evidence from previously published studies and does not involve new human or animal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent to Participate"}},{"value":"All data supporting the findings of this research are derived from publicly available studies, as cited in the article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Conceptualization: MAF and BA. Data curation: TA, RA, and TSM. Formal analysis: MAF. Methodology: BA and MAF. Writing\u00a0\u2013 original draft: MAF. Writing\u00a0\u2013 review and editing: All authors. Supervision: BA.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}